AltruBio lands up to $225M after shift to immune drug research
BioPharma Drive: Drug Pricing
MAY 21, 2024
Since pivoting from oncology, the startup has raised close to $300 million and advanced an ulcerative colitis drug into mid-stage testing.
Drug Research Related Topics 
FTC, in unusual move, leads Sanofi to terminate a drug research deal
BioPharma Drive: Drug Pricing
DECEMBER 12, 2023
Just before clearing Pfizer’s buyout of Seagen, the regulator threatened to block Sanofi’s licensing deal with Maze Therapeutics, a challenge the biotech called ‘‘unprecedented.”
Drug Research 
291
291 Join 15,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pfizer, looking for a jumpstart, leans into cancer drug research
BioPharma Drive: Drug Pricing
MARCH 1, 2024
Reeling from a difficult year financially, the pharma unveiled a new oncology division it says will produce eight billion-dollar medicines by 2030.
Drug Research 225
225 
Foundery, a new biotech venture firm, sets out to speed early immune drug research
BioPharma Drive: Drug Pricing
AUGUST 22, 2023
Billing itself as both a scientific and investment partner, Foundery aims to provide research grants and drug development support to researchers developing new immunotherapies.
Research 246
246 
Pharmas form joint venture to jumpstart Japanese drug research
BioPharma Drive: Drug Pricing
APRIL 22, 2024
A new initiative backed by Takeda, Astellas and Sumitomo Mitsui Banking aims to combat a decade-long decline in drug R&D productivity in Japan.
Drug Research 171
171 
BioAge prices $198M IPO, validating pivot to obesity drug research
BioPharma Drive: Drug Pricing
SEPTEMBER 25, 2024
The offering, which was upsized twice, will support development of a drug the company believes can boost the effects of popular weight loss medicines like Eli Lilly’s Zepbound.
Drug Research 164
164 
Startup Mariana raises $175M for radiopharmaceutical drug research
BioPharma Drive: Drug Pricing
SEPTEMBER 7, 2023
The Series B round makes Mariana one of the best funded private companies in a growing group of biotechs working on new radiopharmaceutical therapies.
Drug Research 164
164 
FogPharma pulls in $145M to support cancer drug research
BioPharma Drive: Drug Pricing
MARCH 1, 2024
The cash will be used to advance development of FOG-001, the company’s lead drug that’s now being tested in an early-stage trial for solid tumors.
Drug Research 164
164 
Sanofi taps Belharra for immune drug research; AstraZeneca’s new cancer drug falls short
BioPharma Drive: Drug Pricing
JUNE 18, 2024
Belharra will use its chemoproteomics technology to identify immune drugs for Sanofi. Elsewhere, Regenxbio mapped a regulatory path and Taysha shared updated results for its Rett treatment.
Drug Research 164
164 
Radiopharma startup Artbio raises $90M in sign of field’s momentum
BioPharma Drive: Drug Pricing
DECEMBER 7, 2023
The funding is indicative of investor interest in an area of drug research that involves at least a dozen startups and multiple publicly traded companies.
Drug Research 323
323 
Backed by billionaires, a new biomedical institute tests an unorthodox approach
BioPharma Drive: Drug Pricing
JANUARY 12, 2024
Arena BioWorks, which will be led by Harvard University scientist Stuart Schreiber, seeks to blend academic and venture capital drug research models.
Drug Research 315
315 
Pfizer to deepen cost cuts as latest sales forecasts miss expectations
BioPharma Drive: Drug Pricing
DECEMBER 13, 2023
The company is now expecting to save $4 billion by the end of 2024, with a majority of the spending cuts coming from drug research and development.
Drug Research 280
280 
Roche launches new Boston center; NIH centralizes peer review
BioPharma Drive: Drug Pricing
MARCH 7, 2025
The Swiss pharma will base cardiometabolic drug research at the new Allston site. Elsewhere, AskBio advanced a gene therapy and Pfizer hired a scientist well versed in GLP-1 science.
Science 221
221 
Drug-Linked Disciplinary Actions by Schools Spiked After Oregon Legalized Marijuana
Drugs.com
OCTOBER 24, 2023
23, 2023 -- New research suggests a link between middle school students being disciplined for marijuana use and legalization of recreational weed, particularly when schools are close to dispensaries that sell the drug. Researchers. MONDAY, Oct.
Drugs 277
277 
Sarepta sells FDA fast pass earned from Duchenne gene therapy approval
BioPharma Drive: Drug Pricing
JULY 5, 2023
The deal enables Sarepta to quickly cash in on the clearance of Elevidys, with $102 million in new funds to help bankroll its drug research.
Therapies 262
262 
Septerna raises $150M to fuel GPCR drug research
BioPharma Drive: Drug Pricing
JULY 11, 2023
RA Capital led a Series B financing round that drew participation from more than a dozen blue-chip venture backers, including new investors Goldman Sachs and Vertex Ventures.
Drug Research 107
107 
Radiopharmaceuticals for cancer: Making radiation precise
BioPharma Drive: Drug Pricing
AUGUST 15, 2023
More than a dozen startups have joined a few publicly traded biotechs and larger pharmaceutical firms in what’s become one of the most competitive areas in drug research.
Drug Research 246
246 Machine Learning‐Based Discovery of a Novel Noncovalent MurA Inhibitor as an Antibacterial Agent
Chemical Biology and Drug Design
MARCH 12, 2025
Therefore, it is an important target for antibacterial drug research. UDP-N-acetylglucosamine 1-carboxyethylene transferase (MurA) is an important enzyme involved in bacterial cell wall synthesis. Although many MurA inhibitors have been discovered, only fosfomycin is still used as a MurA inhibitor in clinical practice.
Drug Research 100
100 
Medicare drug price cuts could have limited early impact, but grow with time
BioPharma Drive: Drug Pricing
AUGUST 16, 2024
Some industry watchers described the level of price discounts announced by Medicare as a "relief," though they warned of bigger future implications for drug research.
Drugs 171
171 
5 questions facing pharma in 2025
BioPharma Drive: Drug Pricing
JANUARY 9, 2025
Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.
Drug Research 164
164 
Otsuka’s startup bet pays off with kidney disease drug results
BioPharma Drive: Drug Pricing
OCTOBER 22, 2024
A medicine the pharma acquired in a $430 million buyout of Visterra in 2018 succeeded in a Phase 3 trial in IgA nephropathy, a crowded corner of drug research.
Disease 156
156 
Allogene taps Arbor in pursuit of ‘off-the-shelf’ CAR-T therapies for autoimmune disease
BioPharma Drive: Drug Pricing
MARCH 12, 2024
Allogene’s partnership with Arbor is designed to help the company stand out in what’s quickly become one of the industry’s hottest areas of drug research.
Therapies 171
171 
Astellas delves deeper into protein degrading drugs with Cullgen deal
BioPharma Drive: Drug Pricing
JUNE 14, 2023
The alliance is Astellas’ second recent partnership involving protein degraders, an emerging area of drug research the company has made a focus in recent years.
Drugs 164
164 
Will Walgreens’ store closures disrupt its clinical trial aims?
BioPharma Drive: Drug Pricing
NOVEMBER 22, 2024
Despite plans to shutter 1,200 stores, the company’s chief clinical trials officer said the pharmacy giant remains committed to aiding drug research.
Clinical Trials 139
139 
Can a Moderna co-founder change the CRO game?
BioPharma Drive: Drug Pricing
FEBRUARY 28, 2024
Well-known scientist and biotech entrepreneur Robert Langer is helping Lindus Health address longstanding challenges in contract drug research.
Drug Research 148
148 
Nexo allies with MD Anderson in pursuit of covalent cancer drugs
BioPharma Drive: Drug Pricing
JULY 26, 2023
The startup, which initially aims to make cancer medicines, claims to have a new twist on covalent drug research.
Drugs 130
130 
Thermo Fisher to buy real-world evidence company CorEvitas for $913M
BioPharma Drive: Drug Pricing
JULY 6, 2023
The contract services provider, which secured the deal through a reportedly competitive process, expects CorEvitas to expand its drug research business.
Drug Research 130
130 
A hybrid evaluation of the intestinal absorption performance of compounds from molecular structure
Chemical Biology and Drug Design
JULY 5, 2024
Abstract Intestinal absorption of compounds is significant in drug research and development. The QSPR model accurately predicted the intestinal absorption of molecules, and the computer simulation found the mechanism of molecular structure affecting intestinal absorption.
Drug Research 100
100 
Product Highlight: DrugBank on Snowflake Marketplace
DrugBank
OCTOBER 30, 2024
This lets you focus on what matters most: driving meaningful results in drug research and development. Your Need for Accessible, High-Quality Data—Solved Pharmaceutical research and healthcare innovation demand timely access to comprehensive, up-to-date data.
Production 74
74 
The Molecular Mechanism of Resveratrol in the Treatment of Chronic Rhinosinusitis Through a Combination of Network Pharmacology and In Vitro Validation
Chemical Biology and Drug Design
FEBRUARY 25, 2025
Together, the present study systematically clarified the possible mechanisms of RES in the treatment of CRS and provided new ideas for the drug research of this disease. A variety of results from cell experiments verified that RES can effectively inhibit the inflammation, oxidative stress and apoptosis of LPS-induced HNEpCs.
Treatment 100
100 
Preclinical vs. Clinical Biomarkers: Understanding Their Distinct Roles in Drug Development
Crown Bioscience
MARCH 14, 2025
These biological indicators, which can be measured in blood, tissues, or other body fluids, serve as critical decision-making tools throughout the drug development pipeline.
Pediatric Development Plans: Key Considerations
Cytel
JUNE 19, 2024
Historically, many drugs have been prescribed to children even though this patient population have largely been excluded from clinical trials. There is an obvious logic. If medicines are to be used in children, they need to be studied in pediatric populations to ensure they are safe and effective.
Drug Channel Implications of the Inflation Reduction Act (NEW Live Video Webinar)
Drug Channels
MARCH 5, 2024
The potential effect of the IRA on manufacturers’ new drug research and development strategies is beyond the scope of this webinar. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Pharmacies and Pharmacy Benefit Managers. Read on for full details on pricing and registration.
Pharmacy 98
98 
Sygnature Discovery’s hit finding expertise in high demand as cardiac biotech customer, River BioMedics, receives an additional €2M seed investment
Sygnature Discovery
SEPTEMBER 14, 2023
Sygnature Discovery is delighted to announce that its customer, River BioMedics , has raised an additional €2M in seed funding to continue its life-saving cardiovascular drug research. The biotech’s aim is to develop medicines that treat the underlying cause of heart failure rather than merely treating the symptoms.
In vivo preclinical models for immune-mediated inflammatory disease drug development
Crown Bioscience
AUGUST 2, 2021
Continue reading to learn more about IMIDs and some of the challenges facing the field, and to review some in vivo preclinical models that can be used to guide IMID drug research and development.
Disease 52
52 
Product Highlight: DrugBank Data Dictionary
DrugBank
SEPTEMBER 12, 2024
Data Exploration If you’re venturing into a new area of drug research, the Data Dictionary helps you identify relevant data fields and understand their context. Together, let’s leverage the power of well-defined, transparent data to accelerate innovation in drug research and development.
Production 82
82 
Distinguishing the Roles of Preclinical vs. Clinical CROs in Clinical Research
Vial
MAY 20, 2024
In this article, we will define preclinical and clinical CROs, as well as highlight the unique needs and challenges of these organizations in their respective stages of drug research. What is a Pre-Clinical CRO? The global preclinical CRO market was estimated to be valued at US$5.7 billion in 2022 and is projected to reach US$10.2
eBook: Unlocking Undruggable Targets
DrugBank
AUGUST 20, 2024
The Power of Drug Repurposing Explore the immense potential of drug repurposing as a strategy for targeting undruggable targets. By identifying new uses for existing drugs, researchers can significantly reduce development time and costs.
Therapies 71
71 
ebook: Never Miss A Hit – Unleash Your Drug Discovery With A Label-Free Playlist
Drug Target Review
APRIL 17, 2023
Featured within this ebook are in-depth application notes as well as the latest research from leading academics and pharmaceutical companies, including: Anders Bach, Associate Professor at the Department of Drug Design and Pharmacology at the University of Copenhagen Researchers from the Francis Crick Institute and GlaxoSmithKline , Dr Andrew Powell, (..)
Why Proactive AME Studies are Critical to Accelerating Your Approval Journey
Conversations in Drug Development Trends
FEBRUARY 21, 2024
As a result, we ensure collection of all urine and fecal samples over a period ranging between five to seven days, modifying the participant diet if needed.
AI in gene delivery vector discovery and design
Drug Target Review
OCTOBER 26, 2023
They can accelerate various aspects of drug research and development, providing novel opportunities for faster and more effective solutions to health challenges. Much like models such as ChatGPT that showcase AI’s vast capabilities in natural language processing and knowledge understanding.
Engineering 105
105 
Possible adulticidal drugs for Onchocerca volvulus
Drug Target Review
SEPTEMBER 21, 2023
She spent one year as a research assistant, focusing on NTDs and one year as a teaching assistant, focusing on Pharmacology. She is currently a lab technician and research assistant at Hallmark Medicals, where she assists in the conducting of Assisted Reproductive Technologies (ARTs) and drug research.
Drugs 105
105 
Unlocking Undruggable Targets: Shifting Paradigms in Modern Drug Discovery
DrugBank
MAY 15, 2024
The binding pockets on KRAS are shallow and polar , not ideal for the kinds of interactions needed for strong, effective drug binding. In fact, it's one of the most exciting areas in drug research today. One approach is to look beyond the traditional drug molecule.
ACTO EXPANDS INVESTMENT IN ARTIFICIAL INTELLIGENCE TO SOLVE UNMET NEEDS IN THE LIFE SCIENCES INDUSTRY
ACTO
SEPTEMBER 11, 2024
“The life sciences industry is actively looking for new ways to leverage AI to bring drugs to market faster to patients waiting in need,” said Parth Khanna, CEO of ACTO. Current solutions are almost exclusively focused on marketing, HCP targeting, workflow automation, and performance insight.
Science 52
52 
Let's personalize your content